Cargando…

Emerging evidence and treatment paradigm of non-small cell lung cancer

Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Si-Yang Maggie, Zheng, Mei-Mei, Pan, Yi, Liu, Si-Yang, Li, Yangqiu, Wu, Yi-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108547/ https://www.ncbi.nlm.nih.gov/pubmed/37069698 http://dx.doi.org/10.1186/s13045-023-01436-2

Ejemplares similares

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
por: Tu, Hai‐Yan, et al.
Publicado: (2023)

A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer
por: Han, Yichao, et al.
Publicado: (2023)

Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer
por: Huang, Shu-Mei, et al.
Publicado: (2017)

Emerging therapies for non-small cell lung cancer
por: Zhang, Chao, et al.
Publicado: (2019)

Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study
por: Zhang, Jia-Tao, et al.
Publicado: (2019)

Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
por: Li, Yang-Si, et al.
Publicado: (2023)

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
por: Zhang, Yi-Chen, et al.
Publicado: (2017)

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial
por: Chen, Cunte, et al.
Publicado: (2022)

Emerging Paradigms in Bioengineering the Lungs
por: Mohgan, Raxshanaa, et al.
Publicado: (2022)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
por: Maggie Liu, Si-Yang, et al.
Publicado: (2023)

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
por: Zhang, Jia-Tao, et al.
Publicado: (2022)

Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases
por: Li, Yang-Si, et al.
Publicado: (2020)

Analysis of gene expression changes associated with human carcinoma-associated fibroblasts in non-small cell lung carcinoma
por: Wu, Xiaofen, et al.
Publicado: (2017)

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
por: Barnet, Megan B., et al.
Publicado: (2018)

Genetic polymorphisms and non-small-cell lung cancer: future paradigms
por: de Mello, Ramon Andrade Bezerra
Publicado: (2014)

Changing paradigm in advanced and metastatic non-small cell lung cancer
por: Uprety, Dipesh, et al.
Publicado: (2020)

Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report
por: Tu, Hai-Yan, et al.
Publicado: (2021)

miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2)
por: He, Xi, et al.
Publicado: (2018)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
por: Liu, Si-Yang, et al.
Publicado: (2020)

Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis
por: Fan, Ruo-Yue, et al.
Publicado: (2021)

The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
por: Dahele, Max, et al.
Publicado: (2011)

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
por: Niu, Fei-Yu, et al.
Publicado: (2015)

Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2023)

MEK inhibitors for the treatment of non-small cell lung cancer
por: Han, Jing, et al.
Publicado: (2021)

Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Wang, Min, et al.
Publicado: (2014)

The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
por: Zhong, Wen-Zhao, et al.
Publicado: (2017)

Enhancement of Radiosurgical Treatment Outcome Prediction Using MRI Radiomics in Patients with Non-Small Cell Lung Cancer Brain Metastases
por: Liao, Chien-Yi, et al.
Publicado: (2021)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies
por: Scarpace, Sarah L
Publicado: (2015)

The evolving treatment paradigm of lung cancer in China
por: Xie, Wei, et al.
Publicado: (2022)

Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer
por: Yang, Shuo, et al.
Publicado: (2022)

Long Noncoding RNA GAS5 Suppresses Tumorigenesis by Inhibiting miR-23a Expression in Non-Small Cell Lung Cancer
por: Mei, Yongcheng, et al.
Publicado: (2017)

microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance
por: Naidu, Srivatsava, et al.
Publicado: (2015)

Emerging role of SIRT2 in non-small cell lung cancer
por: Zheng, Mengge, et al.
Publicado: (2021)

N-linoleyltyrosine resisted the growth of non-small cell lung cancer cells via the regulation of CB(1) and CB(2) involvement of PI3K and ERK pathways
por: Hu, Yan, et al.
Publicado: (2023)

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
por: Yuan, Min, et al.
Publicado: (2019)

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial
por: Chen, Cunte, et al.
Publicado: (2022)

Survival Outcomes of Local Compared With Systemic First Treatment of Non-Small Cell Lung Cancer Brain Metastases
por: Liu, Hong-Mei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_skq66ni7d4iiij0dl6ba3j4gpe